In re Wands: The Eight Factors That Define Undue Experimentation

In re Wands, 858 F.2d 731 (Fed. Cir. 1988), decided September 30, 1988, gave patent law its enduring test for one of the hardest questions under the enablement requirement: how much experimentation is too much? The enablement requirement of 35 U.S.C. Section 112 demands that a patent specification teach a person of ordinary skill how to make and use the full scope of the claimed invention without “undue experimentation.” But some experimentation is always permitted, and the statute does not say where the line falls. In Wands, the Federal Circuit reversed a Patent and Trademark Office rejection of claims to immunoassays using monoclonal antibodies, and in doing so set out eight factors that courts and examiners have used ever since to decide whether required experimentation is reasonable or undue.

At a glance

• Case: In re Wands, 858 F.2d 731 (Fed. Cir. 1988)
• Court: United States Court of Appeals for the Federal Circuit
• Decided: September 30, 1988; opinion by Judge Smith
• Holding: Whether practicing a claim requires undue experimentation is decided by weighing eight factors; on the facts, routine screening of hybridomas to obtain monoclonal antibodies was not undue, so the claims were enabled under 35 U.S.C. Section 112
• Disposition: Reversed the Board’s enablement rejection.

The technology and the rejection

Jack Wands and his co-inventors developed methods for detecting hepatitis B surface antigen using monoclonal antibodies. Monoclonal antibodies are produced by hybridomas, hybrid cells created by fusing an antibody-producing cell with a tumor cell so that the fused cell both makes a single specific antibody and grows indefinitely in culture. To practice the claimed immunoassays, a person would need to make hybridomas that secrete the high-affinity antibodies the claims required, and that step involves screening the hybridomas to identify the ones that produce suitable antibodies.

The PTO rejected the claims for lack of enablement under Section 112. Its theory was that obtaining the needed antibodies required undue experimentation, because making monoclonal antibodies demanded the routine but laborious screening of hybridomas, and success was said to be uncertain. The applicants appealed to the Federal Circuit, arguing that the screening involved was the ordinary, well-understood work of the field, not the kind of open-ended experimentation that defeats enablement.

The enablement requirement and the “undue experimentation” problem

Section 112, first paragraph, requires the specification to describe the invention in terms that enable a person skilled in the art to make and use it. The requirement guards a basic bargain of the patent system: in exchange for the exclusive right, the inventor must fully disclose the invention so that the public can practice it when the patent expires. A specification that leaves a skilled reader to invent the missing pieces, or to conduct a research program to get the claimed invention working, does not deliver on that bargain.

But enablement has never demanded a specification so complete that no experimentation is needed. The law tolerates a “reasonable” amount of experimentation, especially in unpredictable fields like biotechnology and chemistry, where some trial and error is inherent. The doctrinal question, then, is not whether experimentation is required, but whether it is “undue.” That word did the work in Wands, and the court’s contribution was to make it administrable.

The eight Wands factors

The Federal Circuit held that whether experimentation is undue is not measured by a single metric but by weighing a set of factors, taken together, in light of the whole record. The court identified eight:

1. The quantity of experimentation necessary.
2. The amount of direction or guidance presented in the specification.
3. The presence or absence of working examples.
4. The nature of the invention.
5. The state of the prior art.
6. The relative skill of those in the art.
7. The predictability or unpredictability of the art.
8. The breadth of the claims.

No single factor is dispositive. A large quantity of experimentation may still be reasonable if the art is highly skilled, the field is predictable, and the specification supplies strong guidance and working examples. Conversely, even modest experimentation can be undue if the invention is unpredictable, the claims are broad, and the disclosure gives little direction. The factors channel a holistic judgment rather than a mechanical count of experiments, which is why they have proven durable across technologies.

Applying the factors to hybridoma screening

On the record before it, the court concluded that the experimentation needed was not undue. The making of monoclonal antibodies by hybridoma technology was, by 1988, a well-established laboratory technique. The skill in the art was high, and the specification, together with the state of the prior art, provided enough guidance that a skilled worker could obtain the needed antibodies through routine screening. Screening hybridomas to find those producing the desired antibody was tedious but routine; it was the ordinary practice of the field, not a speculative research undertaking. Weighing the factors, the court held that the claims were enabled and reversed the PTO’s rejection. The decision underscored that “routine” screening, however time-consuming, is generally not “undue” when it follows established methods that skilled artisans regularly perform.

Enduring authority and the Amgen backdrop

The Wands factors became the standard framework for enablement at the USPTO and in litigation. The Patent Office incorporated them into the Manual of Patent Examining Procedure at Section 2164, and courts have applied them across mechanical, chemical, and biotechnological arts for more than three decades. They remain the analytical tool through which the abstract “undue experimentation” standard is operationalized.

Enablement returned to the Supreme Court in Amgen Inc. v. Sanofi, 598 U.S. 594 (2023), which addressed how much a specification must teach to enable a broad genus claim, there a claim defined by antibody function rather than structure. The Court held that a specification must enable the full scope of the claims, and that claiming an entire genus by function while disclosing only some members can leave a skilled artisan to undue experimentation. Amgen did not displace Wands; it reinforced the same underlying principle that broad claims demand commensurate disclosure, and it operated against the Wands framework rather than replacing it. As of July 2026, the Wands factors remain the operative enablement test, now read in light of Amgen’s emphasis on full-scope enablement for broad claims.

Open questions

Wands provides a checklist but not a formula, and the tension between its factors and Amgen generates ongoing debate. How should courts reconcile Wands’s tolerance for routine screening with Amgen’s insistence that a specification enable the full scope of a broad functional genus? When does “routine” screening across a large claimed class tip into the “trial and error” the Supreme Court condemned? And because the factors are weighed rather than scored, outcomes can be difficult to predict, especially in unpredictable arts where the breadth-of-claims factor and the guidance factor pull in opposite directions. These questions are actively litigated in the life sciences as of July 2026.

Implications for inventors and businesses

• Match claim breadth to your disclosure. The broader the claim, the more the specification must teach. A narrow claim tightly supported by working examples is easier to enable than a sweeping functional genus.
• Provide guidance and working examples. Two of the eight factors turn directly on the direction the specification gives and the examples it includes. In unpredictable fields, strong working examples are often decisive.
• Routine screening is usually fine. If practicing the invention requires only the established, routine techniques of a skilled field, that ordinarily is not undue experimentation, even if the work is laborious.
• Read Wands with Amgen in mind. For broad functional claims, especially in biotechnology, plan disclosure to enable the full claimed scope, not just a few representative embodiments, to withstand a modern enablement attack.

Frequently asked questions

What are the Wands factors? They are eight considerations for deciding whether the experimentation needed to practice a claim is ‘undue’: the quantity of experimentation, the amount of guidance in the specification, the presence of working examples, the nature of the invention, the state of the prior art, the relative skill in the art, the predictability of the art, and the breadth of the claims.

What did the Federal Circuit decide in In re Wands? It reversed the PTO’s enablement rejection, holding that making the monoclonal antibodies needed to practice the invention required only routine screening of hybridomas, not undue experimentation. Weighing the eight factors, the court found the specification enabling under 35 U.S.C. Section 112.

Are the Wands factors still used? Yes. They are the operative enablement framework at the USPTO, incorporated into MPEP Section 2164, and applied by courts. The Supreme Court engaged with enablement principles in Amgen v. Sanofi in 2023, and the Wands factors remain the standard tool for undue-experimentation analysis as of July 2026.

Authorities and sources

• In re Wands, 858 F.2d 731 (Fed. Cir. 1988). Full-text opinion via Public.Resource.Org.
• 35 U.S.C. Section 112 (written description and enablement).
• USPTO, Manual of Patent Examining Procedure Section 2164 (the enablement requirement and the Wands factors).
• Amgen Inc. v. Sanofi, 598 U.S. 594 (2023) (full-scope enablement of genus claims).
• Quimbee, “In re Wands, 858 F.2d 731 (1988): Case Brief Summary”.